These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 1421428)

  • 1. A phase II study of sulofenur (LY186641) in gastric cancer.
    Kamthan A; Scarffe JH; Walling J; Hatty S; Peters B; Coleman R; Smyth JF
    Anticancer Drugs; 1992 Aug; 3(4):331-5. PubMed ID: 1421428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of sulofenur (LY186641) given orally on a daily x 21 schedule.
    Brown TD; O'Rourke TJ; Kuhn JG; Craig JB; Havlin K; Burris HA; Cagnola J; Hamilton JM; Grindey GB; Satterlee WG
    Anticancer Drugs; 1994 Apr; 5(2):151-9. PubMed ID: 8049498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity and clinical pharmacology of sulofenur in ovarian cancer.
    Taylor CW; Alberts DS; Peng YM; McCloskey TM; Matzner M; Roe DJ; Plezia PM; Grindey GB; Hamilton M; Seitz D
    J Natl Cancer Inst; 1992 Dec; 84(23):1798-802. PubMed ID: 1433369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of the novel sulphonylurea sulofenur in advanced breast cancer.
    Talbot DC; Smith IE; Nicolson MC; Powles TJ; Button D; Walling J
    Cancer Chemother Pharmacol; 1993; 31(5):419-22. PubMed ID: 8431978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of sulofenur and a second generation diarylsulfonylurea, N-[5-(2,3-dihydrobenzofuryl)sulfonyl]-N'-(3,4-dichlorophenyl)urea (LY295501), against colon adenocarcinoma xenografts.
    Houghton PJ; Cheshire PJ; Myers L; Lutz L; Toth J; Grindey GB; Houghton JA
    Anticancer Drugs; 1995 Apr; 6(2):317-23. PubMed ID: 7795279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of sulofenur (LY 186641). A novel antineoplastic agent in advanced non-small cell lung cancer.
    Munshi NC; Seitz DE; Fossella F; Lippman SM; Einhorn LH
    Invest New Drugs; 1993 Feb; 11(1):87-90. PubMed ID: 8394298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I clinical study of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641).
    Hainsworth JD; Hande KR; Satterlee WG; Kuttesch J; Johnson DH; Grindey G; Jackson LE; Greco FA
    Cancer Res; 1989 Sep; 49(18):5217-20. PubMed ID: 2766290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the methemoglobinemia associated with sulofenur.
    Molthrop DC; Wheeler RH; Hall KM; Prchal JT
    Invest New Drugs; 1994; 12(2):99-102. PubMed ID: 7860238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of sulofenur, a novel sulfonylurea, in recurrent epithelial ovarian cancer.
    O'Brien ME; Hardy J; Tan S; Walling J; Peters B; Hatty S; Wiltshaw E
    Cancer Chemother Pharmacol; 1992; 30(3):245-8. PubMed ID: 1628377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of sulofenur (LY186641) in measurable metastatic renal cancer.
    Weinerman B; Eisenhauer E; Stewart D; Mertens W; Tannock I; Venner P; Spaulding R
    Ann Oncol; 1992 Jan; 3(1):83-4. PubMed ID: 1606075
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase II study of sulofenur (LY186641) in untreated patients with extensive small cell lung cancer.
    Shepherd FA; MacCormick R; Eisenhauer EA
    Ann Oncol; 1991; 2(10):772-3. PubMed ID: 1666298
    [No Abstract]   [Full Text] [Related]  

  • 12. Early clinical investigation of sulofenur with a daily schedule in advanced solid tumours.
    Krarup-Hansen A; Pedersen H; Andersen E; Andersen H; Hansen HH
    Invest New Drugs; 1997; 15(2):147-51. PubMed ID: 9220294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641) in humans.
    Hande KR; Kuttesch J; Hamilton M; Satterlee W; Jackson L; Grindey G; Hainsworth JD
    Cancer Res; 1990 Jul; 50(13):3910-4. PubMed ID: 2354440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism and disposition of the anticancer agent sulofenur in mouse, rat, monkey, and human.
    Ehlhardt WJ
    Drug Metab Dispos; 1991; 19(2):370-5. PubMed ID: 1676639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of sulofenur in refractory pediatric malignant solid tumors.
    Pratt CB; Bowman LC; Marina N; Pappo A; Avery L; Luo X; Meyer WH
    Invest New Drugs; 1995; 13(1):63-6. PubMed ID: 7499110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma.
    Jodrell DI; Evans TR; Steward W; Cameron D; Prendiville J; Aschele C; Noberasco C; Lind M; Carmichael J; Dobbs N; Camboni G; Gatti B; De Braud F
    Eur J Cancer; 2004 Aug; 40(12):1872-7. PubMed ID: 15288289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium.
    Kindler HL; Avadhani A; Wade-Oliver K; Karrison T; Mani S; Vokes EE
    Invest New Drugs; 2004 Aug; 22(3):323-7. PubMed ID: 15122080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor diarylsulfonylureas: novel agents with unfulfilled promise.
    Houghton PJ; Houghton JA
    Invest New Drugs; 1996; 14(3):271-80. PubMed ID: 8958182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of the anticancer agent sulofenur in mice, rats, monkeys, and dogs.
    Ehlhardt WJ; Sullivan HR; Wood PG; Woodland JM; Hamilton M; Hamilton C; Cornpropst D; Grindey GB; Worzalla JF; Bewley JR
    J Pharm Sci; 1993 Jul; 82(7):683-8. PubMed ID: 8360840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C.
    Almhanna K; Miron ML; Wright D; Gracian AC; Hubner RA; Van Laethem JL; López CM; Alsina M; Muñoz FL; Bendell J; Firdaus I; Messersmith W; Ye Z; Fasanmade AA; Danaee H; Kalebic T
    Invest New Drugs; 2017 Apr; 35(2):235-241. PubMed ID: 28188407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.